Seoul Pharma Co. Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: -0.064x

Seoul Pharma Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) has a cash flow conversion efficiency ratio of -0.064x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.66 Billion ≈ $-1.80 Million USD) by net assets (₩41.30 Billion ≈ $27.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Seoul Pharma Co. Ltd (2012–2024)

Cash flow conversion efficiency of Seoul Pharma Co. Ltd from 2012 to 2024. This chart illustrates how Seoul Pharma Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 018680 stock price for real-time trading data and today's change.

Seoul Pharma Co. Ltd Cash Flow Conversion Ratio Explained

Seoul Pharma Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Seoul Pharma Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Seoul Pharma Co. Ltd ranked by their cash flow conversion efficiency. Also see Seoul Pharma Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
ASIASOFT CORP.-NVDR-05 F:5ASA	0.039x
Riley Gold Corp V:RLYG	-0.026x
Sebata Holdings Ltd JSE:SEB	0.031x
Quanome Technologies, Inc. NASDAQ:QNME	-0.020x
Biofrontera Inc NASDAQ:BFRI	-0.278x
Research Frontiers Incorporated NASDAQ:REFR	-0.426x
VAIV Co. Inc. KQ:301300	-0.035x
Ozerden Plastik Sanayi IS:OZRDN	0.718x

Annual Cash Flow Conversion Efficiency for Seoul Pharma Co. Ltd (2012–2024)

The table below shows the annual cash flow conversion efficiency of Seoul Pharma Co. Ltd from 2012 to 2024. Review how much free cash does Seoul Pharma Co. Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩40.17 Billion ≈ $27.22 Million	₩-3.01 Billion ≈ $-2.04 Million	-0.075x	-154.86%
2023-12-31	₩38.56 Billion ≈ $26.13 Million	₩5.26 Billion ≈ $3.57 Million	0.137x	+6282.46%
2022-12-31	₩35.42 Billion ≈ $24.00 Million	₩-78.21 Million ≈ $-53.01K	-0.002x	+97.50%
2021-12-31	₩18.96 Billion ≈ $12.85 Million	₩-1.67 Billion ≈ $-1.13 Million	-0.088x	-144.43%
2020-12-31	₩28.85 Billion ≈ $19.55 Million	₩5.74 Billion ≈ $3.89 Million	0.199x	+93.15%
2019-12-31	₩28.45 Billion ≈ $19.28 Million	₩2.93 Billion ≈ $1.98 Million	0.103x	+522.01%
2018-12-31	₩50.31 Billion ≈ $34.10 Million	₩-1.23 Billion ≈ $-831.74K	-0.024x	-15.51%
2017-12-31	₩53.86 Billion ≈ $36.50 Million	₩-1.14 Billion ≈ $-770.77K	-0.021x	+53.00%
2016-12-31	₩42.07 Billion ≈ $28.51 Million	₩-1.89 Billion ≈ $-1.28 Million	-0.045x	-205.98%
2015-12-31	₩33.53 Billion ≈ $22.72 Million	₩1.42 Billion ≈ $963.32K	0.042x	-10.82%
2014-12-31	₩31.10 Billion ≈ $21.08 Million	₩1.48 Billion ≈ $1.00 Million	0.048x	+460.77%
2013-12-31	₩32.25 Billion ≈ $21.86 Million	₩-425.00 Million ≈ $-288.02K	-0.013x	-103.63%
2012-12-31	₩25.38 Billion ≈ $17.20 Million	₩9.22 Billion ≈ $6.25 Million	0.363x	--

About Seoul Pharma Co. Ltd

KQ:018680 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$13.42 Million

₩19.81 Billion KRW

Market Cap Rank

#26152 Global

#1958 in Korea

Share Price

₩1699.00

Change (1 day)

-0.35%

52-Week Range

₩1687.00 - ₩3165.00

All Time High

₩17976.69